UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT~~

TOPursuant ~~SECTION~~to Section 13 ORor 15 (d) OFof ~~THE~~the Securities Exchange Act of 1934

~~SECURITIES~~Date ~~EXCHANGE~~of ~~ACT~~Report: OFOctober ~~1934~~31, 2022

~~Date of Report~~ (Date of earliest event reported)~~: October 27, 2015~~

SANGUI BIOTECH INTERNATIONAL, INC.

(Exact name of ~~Registrant~~registrant as specified in its charter)

Colorado

Colorado	0-21271	84-1330732
(State or other jurisdiction of incorporation or organization)	(Commission file number)	(I.R.S. Employer Identification No.)

~~(State~~Bleichenbrücke or9, ~~Other~~20354 ~~Jurisdiction~~Hamburg, ~~of Incorporation)~~Germany

~~000-21271~~ (Address of principal executive offices)

84011-~~1330732~~ 49-40-46093120

(~~Commission~~Registrant's ~~File~~telephone ~~Number) (IRS~~number, ~~Employer~~including ~~Identification~~area ~~No.~~code)

Alfred-Herrhausen-Str. 44, 58455 Witten, Germany

(Address of Principal Executive Offices) (Zip Code)

011-49-2302-915-204

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~[ ]~~☐ Written ~~communication~~communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~[ ]~~☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~[ ]~~☐ Pre-commencement ~~communication~~communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~[ ]~~☐ Pre-commencement ~~communication~~communications pursuant to Rule ~~13e~~13 e-4(c) under the Exchange Act (17 CFR 240.~~13e~~13 e-4(c))

~~Item~~Securities ~~5.02.~~registered pursuant to Section 12(b) of the Act:

~~Departure~~Title of ~~Directors~~each orclass ~~Principal~~Trading ~~Officers;~~Symbol ~~Election~~Name of ~~Directors;~~exchange on which registered None N/A N/A

~~Appointment~~Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of ~~Principal~~the ~~Officers~~Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]

~~Resignation~~If ofan ~~Chief~~emerging ~~Financial~~growth ~~Officer~~company, ~~and~~indicate ~~Director~~by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

OnItem ~~October 27, 2015, Sangui Biotech International, Inc~~3.01 ~~(the~~Notice ~~“Company”) received the resignation~~ of ~~Joachim~~Delisting ~~Fleing~~or ~~from~~Failure ~~his positions as Chief Financial Officer and Director effective immediately for personal reasons. There were no disagreements on any matter relating~~ to ~~the~~Satisfy ~~Company’s~~a ~~operations,~~Continued ~~policies~~Listing orRule ~~practices between Mr. Fleing and the Company~~ or ~~any~~Standard; ~~officer~~Transfer ~~or director~~ of ~~the Company which led to Mr~~Listing. ~~Fleing’s resignation.~~

~~SIGNATURES~~On October 31, 2022, Sangui BioTech International, Inc. (the “Company” or “Sangui”) was notified by the OTC Markets Group (the “OTC”) that the OTC had determined to commence proceedings to delist its common stock (the “Common Stock”) from the OTCQB as a result of the Company’s failure to comply with the continued listing standard set forth in the OTCQB Standards, Section 2.3(2) which states that the company must “maintain proprietary priced quotations published by a Market Maker in OTC Link with a minimum closing bid price of $.01 per share on at least one of the prior thirty consecutive calendar days.”

~~Pursuant~~On toNovember 2, 2022, the ~~requirements~~Company’s ofCommon ~~the~~Stock ~~Securities~~was ~~Exchange~~automatically ~~Act~~moved ofdown ~~1934~~to, and was available to immediately trade, on the ~~Registrant~~Pink ~~has~~Market, ~~duly~~which ~~caused~~is ~~this~~also ~~report~~operated by OTC Markets Group Inc. The Company will continue to be ~~signed~~traded onunder the symbol “SGBI,” and the Company intends to remain current in its ~~behalf~~Security byand Exchange Commission public reporting requirements following the ~~undersigned~~transfer ~~hereunto~~to ~~duly~~the ~~authorized~~Pink Market.

~~Sangui Biotech International, Inc.~~SIGNATURES

~~/s/~~Pursuant ~~Thomas~~to ~~Striepe~~the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Date:~~SANGUI BIOTECH INTERNATIONAL, INC.

Dated: November 3, ~~2015~~2022/s/ Thomas Striepe

~~____________________________________~~By: Thomas Striepe

~~By:~~Chief ~~Thomas~~Executive ~~Striepe~~Officer and Principal Financial Officer

Its: President

Filing Compare · SANGUI BIOTECH INTERNATIONAL INC